You are here: Industry Insights > Seizures

News List

Medtronic launches ‘brain pacemaker’ implant for reducing epileptic seizures fiercebiotech
February 22, 2019
By delivering controlled electrical pulses to a portion of the brain linked to memory and alertness—and which forms part of a network involved in seizures—Medtronic aims to ....
FDA Approves First Generic Version of Sabril americanpharmaceuticalreview
January 17, 2019
The U.S. Food and Drug Administration (FDA) has approved the first generic version of Sabril (vigabatrin) 500 mg tablets for treating complex partial seizures, also called focal seizures.....
Cannabis-based compound may reduce seizures in children with epilepsy worldpharmanews
December 06, 2018
Interest has been growing in the use of cannabinoids - the active chemicals in cannabis or marijuana - for the treatment of epilepsy in children.
Emergency EEG maker Ceribell raises $35M in series B round fiercebiotech
September 27, 2018
The system's headband includes a “brain stethoscope” feature that converts EEG signals to sound.
Seizures could be stopped and prevented with implanted electronic device europeanpharmaceuticalreview
August 31, 2018
Researchers have developed an electronic device which could help to detect, prevent and stop seizures from occurring in epileptic patients…
FDA Approves New Treatment for Seizures Associated with Dravet Syndrome americanpharmaceuticalreview
August 24, 2018
The US Food and Drug Administration (FDA) approved Diacomit (stiripentol) for the treatment of seizures associated with Dravet syndrome, a rare form of epilepsy.
CBD significantly reduces seizures in patients with severe form of epilepsy europeanpharmaceuticalreview
May 22, 2018
Cannabidiol was shown in a new large-scale, randomised, controlled trial to significantly reduce the number of dangerous seizures in patients with a severe form of epilepsy…
Sunovion Submits sNDA to FDA for Use of APTIOM® for the Treatment of Partial-Onset Seizures in Child americanpharmaceuticalreview
March 14, 2017
Sunovion Pharmaceuticals has submitted a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) to expand the indication for its antiepileptic drug (AED) APTIOM® (eslicarbazepine acetate) to include use as monotherapy or a

Previous page 1 2 Next page